These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37544720)

  • 1. [Fatal invasive pneumococcal disease developed 14 years after allogeneic hematopoietic stem cell transplantation in a patient with myelodysplastic syndrome].
    Hosoda R; Kawamura K; Hara K; Maegaki M; Suzuki S; Hosoda Y; Morishita S; Chikumi H; Motokura T; Fukuda T
    Rinsho Ketsueki; 2023; 64(7):614-618. PubMed ID: 37544720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
    Hiramoto N; Kurosawa S; Tajima K; Okinaka K; Tada K; Kobayashi Y; Shinohara A; Inoue Y; Ueda R; Tanaka T; Kim SW; Yamashita T; Heike Y; Fukuda T
    Eur J Haematol; 2014 Feb; 92(2):137-46. PubMed ID: 24127668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination.
    Konishi T; Sekiya N; Otsuka Y; Konuma R; Wada A; Adachi H; Kishida Y; Nagata A; Yamada Y; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Najima Y; Kobayashi T; Sakamaki H; Ohashi K; Doki N
    Int J Hematol; 2021 Aug; 114(2):263-270. PubMed ID: 33846960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
    Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation.
    Torda A; Chong Q; Lee A; Chen S; Dodds A; Greenwood M; Larsen S; Gilroy N
    Transpl Infect Dis; 2014 Oct; 16(5):751-9. PubMed ID: 25040633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34
    Tamari R; Oran B; Hilden P; Maloy M; Kongtim P; Papadopoulos EB; Rondon G; Jakubowski AA; Andersson BS; Devlin SM; Ahmed S; Popat UR; Ponce D; Chen J; Sauter C; Young JW; de Lima M; Perales MA; O'Reilly RJ; Giralt SA; Champlin RE; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2018 May; 24(5):1079-1087. PubMed ID: 29325829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
    Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
    Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
    Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.
    Kröger N; Zabelina T; van Biezen A; Brand R; Niederwieser D; Martino R; Lim ZY; Onida F; Schmid C; Garderet L; Robin M; van Gelder M; Marks R; Symeonidis A; Kobbe G; de Witte T;
    Haematologica; 2011 Feb; 96(2):291-7. PubMed ID: 20971823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation.
    Morishima S; Kashiwase K; Matsuo K; Azuma F; Yabe T; Sato-Otsubo A; Ogawa S; Shiina T; Satake M; Saji H; Kato S; Kodera Y; Sasazuki T; Morishima Y;
    Haematologica; 2016 Apr; 101(4):491-8. PubMed ID: 26768690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes.
    Sebrango A; Vicuña I; de Laiglesia A; Millán I; Bautista G; Martín-Donaire T; Regidor C; Cabrera R; Fernandez MN
    Best Pract Res Clin Haematol; 2010 Jun; 23(2):259-74. PubMed ID: 20837338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
    Ruutu T; Volin L; Beelen DW; Trenschel R; Finke J; Schnitzler M; Holowiecki J; Giebel S; Markiewicz M; Uharek L; Blau IW; Kienast J; Stelljes M; Larsson K; Zander AR; Gramatzki M; Repp R; Einsele H; Stuhler G; Baumgart J; Mylius HA; Pichlmeier U; Freund M; Casper J
    Haematologica; 2011 Sep; 96(9):1344-50. PubMed ID: 21659356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.